Employee benefit funds have accused Teva Pharmaceuticals of orchestrating a decade-long scheme to delay generic competition for its QVAR asthma inhalers. In a filing to a Massachusetts federal court, the plaintiffs argue that Teva’s recent efforts to dismiss the case only address one aspect of a comprehensive, multipart strategy allegedly designed to stifle competition and maintain market exclusivity. The case sheds light on the broader tactics pharmaceutical companies may employ to extend the profitable lifespans of their branded drugs.
For additional details, please read more here.